Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates

Published 31/07/2025, 17:16
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates

Investing.com -- Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) shares surged 17.6% after the RNAi therapeutics company reported second-quarter earnings that significantly exceeded analyst expectations, driven by strong sales of its ATTR amyloidosis treatments.

The company posted adjusted earnings of $0.32 per share for the quarter ended June 30, 2025, dramatically outperforming the analyst consensus estimate of -$0.59. Revenue reached $773.7 million, substantially above the $643.2 million analysts had projected. Total (EPA:TTEF) net product revenues increased 64% YoY to $672.2 million, primarily fueled by AMVUTTRA’s performance in ATTR cardiomyopathy.

"Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year," said Yvonne Greenstreet, CEO of Alnylam. "While still early in the launch, we are very encouraged by the initial pace of uptake."

AMVUTTRA’s sales reached $492 million, up 114% YoY, while the company’s rare disease drugs GIVLAARI and OXLUMO generated combined revenues of $127.7 million, representing 24% growth compared to the same period last year.

Following these strong results, Alnylam raised its 2025 total net product revenue guidance to $2.65-$2.8 billion, up from the previous range of $2.05-$2.25 billion. This represents expected growth of 61-70% compared to 2024.

The company continues to advance its pipeline, with the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM underway and two additional Phase 3 trials expected to start this year. Alnylam also announced that nucresiran has received Fast Track Designation from the FDA for the treatment of ATTR cardiomyopathy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.